Episode
Ep. 314 Exploring PARP Inhibitor Combinations in Prostate Cancer with Dr. Rana McKay and Dr. Emmanuel Antonarakis
- Podcast
- BackTable Urology
- Published
- Jul 7, 2026
- Duration seconds
- 3099
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/BTL1448570614.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/backtable-urology-3724776/episodes/ep-314-exploring-parp-inhibitor-combinations-in-prostate-cancer-with-dr-rana-mckay-and-dr-emmanuel-antonarakis/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/backtable-urology-3724776/ep-314-exploring-parp-inhibitor-combinations-in-prostate-cancer-with-dr-rana-mckay-and-dr-emmanuel-antonarakis.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
With multiple clinical trials evaluating PARP inhibitor combinations, how do clinicians determine the best approach for advanced prostate cancer? In this episode of BackTable Urology, Dr. Alan Tan is joined by Dr. Rana McKay and Dr. Emmanuel Antonarakis to discuss how evolving evidence, patient selection, timing, toxicity, and genetic testing are shaping the use of PARP inhibitor combinations in clinical practice. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction02:51 - PARPi Basics14:12 - Major Study Differences19:00 - Timing and Selection of PARPi Combinations26:39 - Case: Somatic BRCA2 loss and mHSPC35:51 - Case Continued: BRCA2 Reversion39:57 - BRCAAway Study42:59 - Takeaways from the 2026 APCCC --- More about this episode The conversation reviews lessons learned from major clinical trials, including PROpel, MAGNITUDE, TALAPRO-2, and AMPLITUDE, and addresses how these studies inform real-world treatment choices. The doctors dig into case examples, such as BRCA2 loss and reversion, and highlight practical strategies for using germline and somatic testing to personalize care. Key insights from the 2026 Advanced Prostate Cancer Consensus Conference are also shared, emphasizing the importance of precision medicine in this rapidly evolving field. --- Resources Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel) https://clinicaltrials.gov/study/NCT03732820 A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE) https://clinicaltrials.gov/study/NCT03748641?tab…